Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
5.61
-0.02 (-0.36%)
At close: Nov 20, 2024, 4:00 PM
5.85
+0.24 (4.27%)
After-hours: Nov 20, 2024, 7:55 PM EST
Company Description
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company.
The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma.
It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.
The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.
Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited
| Country | Australia |
| Founded | 1994 |
| IPO Date | Jan 6, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | John Friend |
Contact Details
Address: Three International Towers, Level 24 Sydney, NSW 2000 Australia | |
| Phone | 61 2 9472 4101 |
| Website | kaziatherapeutics.com |
Stock Details
| Ticker Symbol | KZIA |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 0001055886 |
| CUSIP Number | 48669G105 |
| ISIN Number | US48669G1058 |
| SIC Code | 8880 |
Key Executives
| Name | Position |
|---|---|
| Dr. John Edwin Friend II, M.D. | Chief Executive Officer, MD and Director |
| Gabrielle Heaton BBUS (ACC), CPA | Principal Accounting Officer, Vice President of Finance and Administration and Principal Financial Officer |
| Anna Sandham | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2024 | 424B3 | Prospectus |
| Oct 16, 2024 | 424B3 | Prospectus |
| Oct 16, 2024 | 424B3 | Prospectus |
| Nov 21, 2017 | 424B3 | Prospectus |
| Nov 17, 2017 | 424B3 | Prospectus |
| Jul 11, 2017 | 424B3 | Prospectus |
| Jun 6, 2016 | F-6 POS | Post-effective amendments for immediately effective filing |